Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects

Medical Hypotheses

Volumn 66, Issue 3, 2006, Pages 495-500

  Ye, Hui Jun ^a   Zhao, Shui Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR AP 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR LESION; VASCULAR SMOOTH MUSCLE;

ADIPOCYTES; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CLOFIBRIC ACID; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MACROPHAGES; MODELS, BIOLOGICAL; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; T-LYMPHOCYTES;

EID: 30344466045     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.09.036     Document Type: Article

References (62)

1. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, and P. Helo Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
2. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, and M.B. Elam Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group N Engl J Med 341 1999 410 418
3. M.H. Frick, M. Syvanne, M.S. Nieminen, H. Kauma, S. Majahalme, and V. Virtanen Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid coronary angiography trial (LOCAT) study group Circulation 96 1997 2137 2143
4. U. de Faire, C.G. Ericsson, L. Grip, J. Nilsson, B. Svane, and A. Hamsten Retardation of coronary atherosclerosis: the bezafibrate coronary atherosclerosis intervention trial (BECAIT) and other angiographic trials Cardiovasc Drugs Ther 11 Suppl. 1 1997 257 263
5. C.G. Ericsson, A. Hamsten, J. Nilsson, L. Grip, B. Svane, and U. de Faire Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients Lancet 347 1996 849 853
6. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001;357:905-10.
7. P.J. Barter Antiatherogenic properties of fibrates Arterioscler Thromb Vasc Biol 25 2005 1095 1096
8. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
9. P. Libby, and P. Theroux Pathophysiology of coronary artery disease Circulation 111 2005 3481 3488
10. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
11. G.J. Blake, and P.M. Ridker Inflammatory bio-markers and cardiovascular risk prediction J Intern Med 252 2002 283 294
12. P. Libby Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
13. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 2005 1685 1695
14. J. Malik, V. Melenovsky, D. Wichterle, T. Haas, J. Simek, and R. Ceska Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT) Cardiovasc Res 52 2001 290 298
15. N. Marx, B. Kehrle, K. Kohlhammer, M. Grub, W. Koenig, and V. Hombach PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis Circ Res 90 2002 703 710
16. M.F. Linton, and S. Fazio Macrophages, inflammation, and atherosclerosis Int J Obes Relat Metab Disord 27 Suppl. 3 2003 S35 S40
17. N. Marx, G.K. Sukhova, T. Collins, P. Libby, and J. Plutzky PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 99 1999 3125 3131
18. S. Li, N. Gokden, M.D. Okusa, R. Bhatt, and D. Portilla Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF Am J Physiol Renal Physiol 289 2005 F469 F480
19. B. Okopien, J. Kowalski, R. Krysiak, K. Labuzek, A. Stachura-Kulach, and A. Kulach Monocyte suppressing action of fenofibrate Pharmacol Rep 57 2005 367 372
20. S.P. Zhao, H.J. Ye, H.N. Zhou, S. Nie, and Q.Z. Li Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease Clin Chim Acta 332 2003 61 67
21. P. Delerive, K. De Bosscher, S. Besnard, W. Vanden Berghe, J.M. Peters, and F.J. Gonzalez Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1 J Biol Chem 274 1999 32048 32054
22. H. Shu, B. Wong, G. Zhou, Y. Li, J. Berger, and J.W. Woods Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells Biochem Biophys Res Commun 267 2000 345 349
23. C. Delayre-Orthez, J. Becker, I. Guenon, V. Lagente, J. Auwerx, and N. Frossard PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse Respir Res 6 2005 91
24. G. Chinetti, S. Griglio, M. Antonucci, I.P. Torra, P. Delerive, and Z. Majd Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages J Biol Chem 273 1998 25573 25580
25. S. Stemme, B. Faber, J. Holm, O. Wiklund, J.L. Witztum, and G.K. Hansson T lymphocytes from human atherosclerotic plaques recognize oxidized low-density lipoprotein Proc Natl Acad Sci USA 92 1995 3893 3897
26. G.K. Hansson Regulation of immune mechanisms in atherosclerosis Ann N Y Acad Sci 947 2001 157 165
27. S.J. Szabo, B.M. Sullivan, S.L. Peng, and L.H. Glimcher Molecular mechanisms regulating Th1 immune responses Ann Rev Immunol 21 2003 713 758
28. J.D. Ochrietor, K.A. Harrison, K. Zahedi, and R.F. Mortensen Role of STAT3 and C/EBP in cytokine-dependent expression of the mouse serum amyloid P-component (SAP) and C-reactive protein (CRP) genes Cytokine 12 2000 888 899
29. E.S. Biegelsen, and J. Loscalzo Endothelial function and atherosclerosis Coron Artery Dis 10 1999 241 256
30. E.E. Eriksson, E. Karlof, K. Lundmark, P. Rotzius, U. Hedin, and X. Xie Powerful inflammatory properties of large vein endothelium in vivo Arterioscler Thromb Vasc Biol 25 2005 723 728
31. K. Goya, S. Sumitani, X. Xu, T. Kitamura, H. Yamamoto, and S. Kurebayashi Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells Arterioscler Thromb Vasc Biol 24 2004 658 663
32. P. Delerive, F. Martin-Nizard, G. Chinetti, F. Trottein, J.C. Fruchart, and J. Najib Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway Circ Res 85 1999 394 402
33. F. Martin-Nizard, C. Furman, P. Delerive, A. Kandoussi, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells J Cardiovasc Pharmacol 40 2002 822 831
34. A. Zampetaki, Z. Zhang, Y. Hu, and Q. Xu Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-kappaB signaling pathways Am J Physiol Heart Circ Physiol 288 2005 H2946 H2954
35. S. Bousserouel, M. Raymondjean, A. Brouillet, G. Bereziat, and M. Andreani Modulation of cyclin D1 and early growth response factor-1 gene expression in interleukin-1beta-treated rat smooth muscle cells by n - 6 and n - 3 polyunsaturated fatty acids Eur J Biochem 271 2004 4462 4473
36. A.D. Schecter, A.B. Berman, and M.B. Taubman Chemokine receptors in vascular smooth muscle Microcirculation 10 2003 265 272
37. M. Cattaruzza, K. Schafer, and M. Hecker Cytokine-induced down-regulation of zfm1/splicing factor-1 promotes smooth muscle cell proliferation J Biol Chem 277 2002 6582 6589
38. G.E. Rainger, P. Stone, C.M. Morland, and G.B. Nash A novel system for investigating the ability of smooth muscle cells and fibroblasts to regulate adhesion of flowing leukocytes to endothelial cells J Immunol Methods 255 2001 73 82
39. R. Kranzhofer, J. Schmidt, C.A. Pfeiffer, S. Hagl, P. Libby, and W. Kubler Angiotensin induces inflammatory activation of human vascular smooth muscle cells Arterioscler Thromb Vasc Biol 19 1999 1623 1629
40. D.B. Landry, L.L. Couper, S.R. Bryant, and V. Lindner Activation of the NF-kappaB and I kappaB system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 Am J Pathol 151 1997 1085 1095
41. J.M. Breuss, M. Cejna, H. Bergmeister, A. Kadl, G. Baumgartl, and S. Steurer Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model Circulation 105 2002 633 638
42. U. Zeiffer, A. Schober, M. Lietz, E.A. Liehn, W. Erl, and N. Emans Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines Circ Res 94 2004 776 784
43. B.E. Rolfe, J.D. Muddiman, N.J. Smith, G.R. Campbell, and J.H. Campbell ICAM-1 expression by vascular smooth muscle cells is phenotype-dependent Atherosclerosis 149 2000 99 110
44. E.W. Raines, and N. Ferri Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease J Lipid Res 46 2005 1081 1092
45. X. Wang, G.Z. Feuerstein, J.L. Gu, P.G. Lysko, and T.L. Yue Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells Atherosclerosis 115 1995 89 98
46. H. Li, M.W. Freeman, and P. Libby Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines J Clin Invest 95 1995 122 133
47. Y. Wang, K.A. Lindstedt, and P.T. Kovanen Mast cell granule remnants carry LDL into smooth muscle cells of the synthetic phenotype and induce their conversion into foam cells Arterioscler Thromb Vasc Biol 15 1995 801 810
48. B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret, and I.P. Torra Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators Nature 393 1998 790 793
49. R. Kranzhofer, S.K. Clinton, K. Ishii, S.R. Coughlin, J.W. Fenton, and P. Libby Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes Circ Res 79 1996 286 294
50. D. Lepailleur-Enouf, O. Valdenaire, M. Philippe, M. Jandrot-Perrus, and J.B. Michel Thrombin induces endothelin expression in arterial smooth muscle cells Am J Physiol Heart Circ Physiol 278 2000 H1606 H1612
51. S. Ryoo, M. Won, D.U. Kim, L. Kim, G. Han, and S.K. Park PPARalpha activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells Biochem Biophys Res Commun 318 2004 329 334
52. A. Cabrero, M. Alegret, R.M. Sanchez, T. Adzet, J.C. Laguna, and M. Vazquez Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes Diabetes 50 2001 1883 1890
53. S.P. Zhao, and J. Wu Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits Clin Chim Acta 347 2004 145 150
54. Y. Shirai, S. Yaku, and M. Suzuki Metabolic regulation of leptin production in adipocytes: a role of fatty acid synthesis intermediates J Nutr Biochem 15 2004 651 656
55. P. Trayhurn Endocrine and signalling role of adipose tissue: new perspectives on fat Acta Physiol Scand 184 2005 285 293
56. H. Hauner Secretory factors from human adipose tissue and their functional role Proc Nutr Soc 64 2005 163 169
57. G. Fantuzzi Adipose tissue, adipokines, and inflammation J Allergy Clin Immunol 115 2005 911 919
58. V. Sharma, and J.H. McNeill The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology Curr Vasc Pharmacol 3 2005 169 180
59. Y. Matsuzawa Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease Atheroscler Suppl 6 2005 7 14
60. N. Ouchi, S. Kihara, T. Funahashi, Y. Matsuzawa, and K. Walsh Obesity, adiponectin and vascular inflammatory disease Curr Opin Lipidol 14 2003 561 566
61. J. Nedvidkova, K. Smitka, V. Kopsky, and V. Hainer Adiponectin, an adipocyte-derived protein Physiol Res 54 2005 133 140
62. Y. Mori, F. Oana, A. Matsuzawa, S. Akahane, and N. Tajima Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity Endocrine 25 2004 247 251